United States

Indian pharmaceutical major Cipla has initiated a recall of a cancer treatment drug in the United States after regulatory authorities identified manufacturing-related concerns. According to information released by the U.S. Food and Drug Administration, the recall was issued as part of routine quality surveillance designed to ensure the safety and efficacy of medicines distributed in the American market. While the recall does not necessarily indicate widespread harm to patients, it highlights the stringent compliance standards required for pharmaceutical companies operating globally.

Hyderabad-based drugmaker NATCO Pharma has strengthened its presence in the United States by launching a generic version of a high-value oncology medication, marking a strategic milestone in its global expansion. The product introduction positions the company to capitalize on patent expirations in the U.S. pharmaceutical market while broadening access to cost-effective cancer treatments. The launch is expected to contribute meaningfully to revenue growth, given the significant annual sales of the branded reference drug.

Samsung Electronics has rolled out its Galaxy S26 series smartphones in the U.S. and South Korea, incorporating a suite of advanced artificial intelligence features designed to enhance user experience, performance, and personalization. The new functionalities include AI-powered photography, predictive battery management, and intelligent task automation, signaling Samsung’s continued investment in integrating machine learning into its flagship devices.

Glenmark Pharmaceuticals has strengthened its presence in the United States by launching a generic version of Sodium Phosphates Injection, broadening its injectable product portfolio in the world’s largest pharmaceutical market. The launch follows regulatory approval and underscores the company’s strategy of targeting niche, hospital-focused formulations with limited competition. Industry analysts view the move as part of Glenmark’s ongoing pivot toward complex generics and specialty products that offer stronger margins. As pricing pressures persist in the U.S.

Skywatchers across the United States will witness a total lunar eclipse on March 3, as the Moon passes fully into Earth’s shadow in a striking astronomical display. The phenomenon, visible without specialized equipment, is expected to draw widespread public interest and drive participation in observatory events nationwide.

Gold prices climbed sharply to around Rs. 5,230 in early Asian trading Thursday, propelled by escalating geopolitical tensions and renewed uncertainty over U.S. trade policy. The rally follows a U.S. Supreme Court ruling that deemed sweeping tariffs introduced by President Donald Trump unlawful, only for the administration to respond with a fresh 15 percent levy effective immediately. The abrupt policy reversal has unsettled global markets and revived demand for safe-haven assets. Investors are now turning their attention to the upcoming U.S.

The clash between the United States and Namibia in the ICC Men's T20 World Cup reflects the tournament’s broader narrative of expansion and opportunity. Both teams enter the fixture with realistic aspirations of advancing beyond the group stage, making the contest strategically significant. For the USA, the match is a test of consistency and composure, while Namibia see it as a chance to reaffirm their credentials after recent global appearances.

Reliance Industries Ltd. has obtained a U.S. government license permitting it to import crude oil from Venezuela, marking a significant development in global energy trade flows. The authorization comes amid evolving geopolitical dynamics and calibrated sanctions relief tied to Venezuela’s oil sector. For Reliance, access to Venezuelan crude offers feedstock flexibility and potential cost advantages for its complex refining operations. The move could recalibrate sourcing strategies while reinforcing India’s energy security objectives.

The United States’ decision to remove import duties on select Indian goods effective Feb. 7 marks a notable shift in bilateral trade relations and a renewed emphasis on economic cooperation. The move is expected to ease cost pressures for exporters, improve price competitiveness in the U.S. market, and reinforce supply-chain ties between the two economies. While the scope of products covered has not been fully detailed, the policy change underscores Washington’s intent to recalibrate trade engagement with New Delhi amid broader geopolitical and commercial realignments.

Natco Pharma Ltd. has received approval from the U.S. Food and Drug Administration for a cancer treatment, marking a significant regulatory milestone for the Indian drugmaker. The clearance allows the company to market the product in the United States, one of the world’s most competitive pharmaceutical markets. Analysts said the approval enhances Natco’s oncology portfolio and could support revenue growth through regulated-market sales.